Novartis Receives FDA Complete Response Letter on Inclisiran Novartis Receives FDA Complete Response Letter on Inclisiran

The FDA was unable to approve the new drug application for inclisiran, a novel treatment to lower LDL cholesterol, owing to unresolved facility inspection concerns, the company said.News Alerts
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news